JG
FULC icon

Jain Global’s Fulcrum Therapeutics FULC Stock Holding History

Jain Global’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,260
Closed -$467K – 1365
2025
Q4 		$467K Buy
+41,260
New +$420K ﹤0.01% 850
2025
Q2 		– Sell
-13,051
Closed -$37.6K – 1339
2025
Q1 		$37.6K Sell
13,051
-2,358
-15% -$8.66K ﹤0.01% 1023
2024
Q4 		$72.4K Buy
+15,409
New +$56.8K ﹤0.01% 704

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Jain Global's FULC Position: Q1 2026 in Review

Jain Global sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 41,260 shares — an estimated $467K sold.

Jain Global first reported a position in FULC in Q4 2024 and held it in 3 quarters. The position peaked at $467K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Jain Global reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jain Global sold 41,260 Fulcrum Therapeutics shares in Q1 2026, an estimated $467K.
  • Jain Global first reported a position in Fulcrum Therapeutics in Q4 2024 and held it in 3 quarters.
  • Jain Global's Fulcrum Therapeutics position peaked at $467K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.